
Jade Biosciences, Inc. (NASDAQ:JBIO – Free Report) – Equities researchers at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Jade Biosciences in a research note issued to investors on Monday, November 16th. HC Wainwright analyst A. He now anticipates that the company will post earnings per share of ($2.25) for the year, up from their previous estimate of ($2.41). HC Wainwright currently has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Jade Biosciences’ current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Jade Biosciences’ Q4 2026 earnings at ($0.53) EPS, Q1 2027 earnings at ($0.54) EPS, Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.56) EPS, Q4 2027 earnings at ($0.57) EPS, FY2027 earnings at ($2.22) EPS, FY2028 earnings at ($2.32) EPS, FY2029 earnings at ($2.37) EPS and FY2030 earnings at ($1.85) EPS.
Jade Biosciences (NASDAQ:JBIO – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.31.
Read Our Latest Stock Analysis on JBIO
Jade Biosciences Stock Up 0.4%
JBIO opened at $15.40 on Wednesday. Jade Biosciences has a 12-month low of $11.02 and a 12-month high of $28.00. The firm’s fifty day moving average price is $15.15 and its 200 day moving average price is $18.14.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the stock. Bellevue Group AG increased its position in Jade Biosciences by 40.4% during the third quarter. Bellevue Group AG now owns 4,293,937 shares of the company’s stock worth $60,330,000 after buying an additional 1,235,941 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Jade Biosciences in the 1st quarter worth approximately $43,557,000. Pictet Asset Management Holding SA boosted its position in Jade Biosciences by 64.4% during the third quarter. Pictet Asset Management Holding SA now owns 1,205,972 shares of the company’s stock worth $16,944,000 after purchasing an additional 472,204 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Jade Biosciences by 22.0% in the third quarter. Goldman Sachs Group Inc. now owns 896,834 shares of the company’s stock valued at $12,601,000 after purchasing an additional 161,610 shares during the period. Finally, Jump Financial LLC lifted its position in Jade Biosciences by 75.3% during the 3rd quarter. Jump Financial LLC now owns 302,812 shares of the company’s stock worth $4,255,000 after acquiring an additional 130,065 shares during the last quarter.
Key Headlines Impacting Jade Biosciences
Investors following JBIO have been watching these headlines:
- Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $2.25 from a loss of $2.41, while retaining its Buy rating and $55 target. Wall Street Zen also upgraded the stock. Jade Biosciences upgraded at Wall Street Zen
- Neutral Sentiment: Analyst coverage described JBIO as carrying a “Moderate Buy” consensus, suggesting supportive sentiment remains despite recent estimate revisions. Jade Biosciences receives Moderate Buy rating
- Negative Sentiment: HC Wainwright trimmed estimates for Q4 2026 and each quarter of 2027, as well as FY2027–FY2030, generally projecting slightly larger losses. Guggenheim also cut its price target to $41 from $47, though it kept a Buy rating. The revisions may weigh on shares by signaling higher expected losses; the retained Buy ratings and targets provide some counterbalance. Guggenheim forecast for Jade Biosciences
Jade Biosciences Company Profile
Jade Biosciences is a biotechnology company developing antibody-based treatments for autoimmune diseases. Its research focuses on targets involved in immune activity that can contribute to chronic disease. The company’s lead program, JADE101, is an antibody designed to block APRIL, a protein involved in the production of antibodies. Jade is developing the candidate for IgA nephropathy, a kidney disease in which abnormal IgA antibodies can damage the kidneys. Jade’s pipeline is focused on potential therapies for autoimmune conditions.
Further Reading
- Five stocks we like better than Jade Biosciences
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Jade Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jade Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
